Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cytochrome P450, family 2, subfamily C, polypeptide 9 | Starlite/ChEMBL | References |
Homo sapiens | nicotinamide phosphoribosyltransferase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Probable cytochrome P450 136 Cyp136 | cytochrome P450, family 2, subfamily C, polypeptide 9 | 490 aa | 441 aa | 21.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | diacylglycerol kinase catalytic domain-containing protein | 0.0056 | 0 | 0.5 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.1623 | 0.5816 | 1 |
Echinococcus multilocularis | sphingosine kinase 1 | 0.1443 | 0.5149 | 0.5149 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1173 | 0.4147 | 0.4147 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.1623 | 0.5816 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1443 | 0.5149 | 0.5149 |
Toxoplasma gondii | diacylglycerol kinase accessory domain (presumed) domain-containing protein | 0.0056 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1576 | 0.5644 | 0.5644 |
Echinococcus granulosus | nicotinamide phosphoribosyltransferase | 0.0418 | 0.1343 | 0.1343 |
Mycobacterium tuberculosis | Nicotinic acid phosphoribosyltransferase PncB2 | 0.0078 | 0.0079 | 0.0154 |
Schistosoma mansoni | sphingoid long chain base kinase | 0.1443 | 0.5149 | 0.5149 |
Leishmania major | nicotinate phosphoribosyltransferase, putative | 0.0078 | 0.0079 | 0.0079 |
Schistosoma mansoni | nicotinate phosphoribosyltransferase related pre-B cell enhancing factor | 0.0418 | 0.1343 | 0.1343 |
Treponema pallidum | nicotinate phosphoribosyltransferase | 0.0078 | 0.0079 | 0.5 |
Schistosoma mansoni | sphingosine kinase A B | 0.1443 | 0.5149 | 0.5149 |
Giardia lamblia | Hypothetical protein | 0.1623 | 0.5816 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2749 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1173 | 0.4147 | 0.4147 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1173 | 0.4147 | 0.4147 |
Mycobacterium ulcerans | hypothetical protein | 0.1443 | 0.5149 | 0.8853 |
Brugia malayi | Pre-B cell enhancing factor precursor | 0.0418 | 0.1343 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.2703 | 0.9828 | 0.9828 |
Plasmodium falciparum | nicotinate phosphoribosyltransferase, putative | 0.0078 | 0.0079 | 1 |
Toxoplasma gondii | diacylglycerol kinase, putative | 0.0056 | 0 | 0.5 |
Mycobacterium tuberculosis | Conserved protein | 0.1443 | 0.5149 | 1 |
Plasmodium vivax | diacylglycerol kinase, putative | 0.0056 | 0 | 0.5 |
Entamoeba histolytica | nicotinate phosphoribosyltransferase, putative | 0.0078 | 0.0079 | 0.0136 |
Plasmodium vivax | diacylglycerol kinase, putative | 0.0056 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein, conserved | 0.1443 | 0.5149 | 0.8853 |
Schistosoma mansoni | nicotinate phosphoribosyltransferase related pre-B cell enhancing factor | 0.0078 | 0.0079 | 0.0079 |
Onchocerca volvulus | 0.2749 | 1 | 1 | |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2749 | 1 | 1 |
Trichomonas vaginalis | nicotinate phosphoribosyltransferase, putative | 0.0078 | 0.0079 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2749 | 1 | 1 |
Mycobacterium tuberculosis | Nicotinic acid phosphoribosyltransferase PncB1 | 0.0078 | 0.0079 | 0.0154 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.2749 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2749 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.2749 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.2703 | 0.9828 | 0.9828 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2703 | 0.9828 | 0.9828 |
Giardia lamblia | Hypothetical protein | 0.1623 | 0.5816 | 0.5 |
Echinococcus granulosus | sphingosine kinase 1 | 0.1443 | 0.5149 | 0.5149 |
Mycobacterium ulcerans | hypothetical protein | 0.1623 | 0.5816 | 1 |
Echinococcus multilocularis | nicotinamide phosphoribosyltransferase | 0.0418 | 0.1343 | 0.1343 |
Trypanosoma brucei | nicotinate phosphoribosyltransferase, putative | 0.0078 | 0.0079 | 0.0079 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.2703 | 0.9828 | 0.9828 |
Schistosoma mansoni | nicotinate phosphoribosyltransferase | 0.0078 | 0.0079 | 0.0079 |
Loa Loa (eye worm) | pre-B cell enhancing factor | 0.0418 | 0.1343 | 0.1343 |
Trypanosoma cruzi | nicotinate phosphoribosyltransferase, putative | 0.0078 | 0.0079 | 0.0079 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.2703 | 0.9828 | 0.9828 |
Schistosoma mansoni | 6-phosphofructokinase | 0.2749 | 1 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-1-like protein | 0.1173 | 0.4147 | 0.4147 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CL (ADMET) | = 48 ml/min.kg | Hepatic clearance in CD-1 mouse liver microsomes at 1 uM after 20 to 60 mins by LC-MS/MS analysis | ChEMBL. | 23668988 |
IC50 (functional) | = 99 nM | Antiproliferative activity against human A2780 cells after 72 hrs by sulforhodamine B assay | ChEMBL. | 23668988 |
IC50 (binding) | = 100 nM | Inhibition of NAMPT (unknown origin) assessed as NAM conversion to NMN preincubated for 15 mins prior to substrate addition measured after 30 mins by mass spectrophotometric analysis | ChEMBL. | 23668988 |
IC50 (ADMET) | = 2180 nM | Inhibition of CYP2C9 in human liver microsomes after 30 mins | ChEMBL. | 23668988 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 23668988 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.